SuperworthDogwood Therapeutics EPS DWTX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$8.95
- Latest quarter, Q2 FY26
- −$0.34
- Fiscal year 2025
- −$18.90
Dogwood Therapeutics' earnings per share was −$8.95 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.34.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$18.90 | n/a |
| FY2024 | −$11.17 | n/a |
| FY2023 | −$3.21 | n/a |
| FY2022 | −$1.31 | n/a |
| FY2021 | −$1.91 | n/a |
| FY2020 | −$2.05 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.34 | n/a | −$8.95 | |
| Q1 FY26 | −$0.15 | n/a | −$10.60 | |
| Q4 FY25 | −$0.26 | n/a | −$18.90 | |
| Q3 FY25 | −$8.20 | n/a | −$24.93 | |
| Q2 FY25 | −$1.99 | n/a | −$18.78 | |
| Q1 FY25 | −$8.45 | n/a | −$17.94 | |
| Q4 FY24 | −$6.29 | n/a | −$11.17 | |
| Q3 FY24 | −$2.05 | n/a | −$6.31 | |
| Q2 FY24 | −$1.15 | n/a | −$5.88 | |
| Q1 FY24 | −$1.68 | n/a | −$4.81 | |
| Q4 FY23 | −$1.43 | n/a | −$3.21 | |
| Q3 FY23 | −$1.62 | n/a | −$1.89 |
Against its peers
Companies in Drug Manufacturers - General nearest Dogwood Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| DWTXDogwood Therapeutics | −$8.95 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Dogwood Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.